Table 6.
The combined synergizing effects of Obatoclax on cellular apoptosis
| Cancer | Cell Type | Combined | Apoptosis | Ref |
|---|---|---|---|---|
| AML | U937, HL-60, MV4–11 | sorafenib | – | [195] |
| Bladder | HT1197 | paclitaxel | – | [196] |
| Bladder | T24, TCCSuP, 5637 | cisplatin | – | [197] |
| Cholangiocarcinoma | KMCH, KMBC, TFK, | TRAIL | – | [198] |
| Colon | HCT116, HCT-8, | fluorouracil | – | [199] |
| Esophageal | CaES-17 | MG132 | – | [200] |
| Glioblastoma | Patient samples | SAHA, LBH589 | – | [201] |
| Small cell lung | H82, H526, DMS79, H196, H1963, H69 | bortezomib and carfilzomib | synergized | [202] |
| Non-small cell Lung | LoVo, RKO, HCT116 | oxaliplatin resistance | – | [203] |
| Neuroblastoma | SK-N-DZ, IGR-NB8 |
hydroxychloroquine/cisplatin/ doxorubicin |
– | [204] |
| Pancreas | BxPC-3 | gemcitabine | – | [205] |
| Pancreas | PANC-1 and BxPC-3 | TRAIL | – | [206] |
| Pancreas | BxPC-3, HPAC | chloroquine | – | [207] |
| Pancreas | BxPC-3, HPAC, MIAPaCa-2, PANC-1, AsPC-1, CFPAC-1 | AZD2281 | synergized | [208] |
| Thyroid | KTC-1, BCPAP | LY3009120/vemurafenib resistance | – | [209] |
The cancer types are highlighted in bold (left column), non-synergy is highlighted by ‘-‘and the corresponding studies are referenced in the column on the right (Ref). Abbreviations: AML Acute Myelogenous Leukemia